(Reuters) – The United States asked on Tuesday to delay the deadline for a World Trade Organization resolution on the production of COVID-19 remedies and tests, the U. S. Trade Representative said.
“Real questions remain on a variety of issues, and the longer, along with USITC data, it will help the world make a more informed resolution on whether extending the ministerial resolution to COVID-19 treatments and diagnostics would result in better outcomes for those products,” U. S. Ambassador Katharine Tai said in a statement. referring to the United States International Trade Commission.
An agreement reached over the summer on a partial waiver of intellectual asset rights for COVID-19 vaccines, as well as safe rights for tests and medicines.
A six-month deadline had been set to agree to extend the partial waiver of intellectual property, Reuters reported earlier, presenting a document shared with other WTO members.
The USITC will examine the “key components, production process, intellectual asset protections, and a description of the origin chain,” as well as data on global production and production data, and data on the global market for COVID-19 products, among other areas. , the USTR office said.
Tai’s workplace said it had arguments from both supporters and warring parties to extend the WTO ruling and that “in any case, the perspectives are on the formula as a whole, whether existing WTO intellectual asset protections are a barrier to access to medicines or an indispensable component of innovation.
The two sides also presented their perspectives on “the express characteristics of the COVID-19 diagnostics and treatment markets,” it said in the statement.
(Washington Press Office; Editing by Bernadette Baum)
This site is through reCAPTCHA and Google’s Privacy Policy and Terms of Service apply.